Neuro-Inflammation
A Positive Blood Test for Alzheimer's Tau Is Not a False Alarm — Even in Other Dementias
A Harvard/Mass General autopsy study of 187 participants confirms that plasma pTau217 — a leading blood-based Alzheimer's biomarker — accurately reflects actual Alzheimer's brain pathology even when another dementia is the primary diagnosis. When pTau217 was elevated in patients with Lewy body disease, TDP-43, or vascular dementia, autopsy revealed that the vast majority also carried concurrent Alzheimer's changes. By contrast, GFAP was elevated across nearly all dementia types regardless of Alzheimer's pathology, making it a non-specific marker. NfL showed no consistent link to Alzheimer's pathology at all. These findings reframe how clinicians should interpret blood biomarker results in complex, mixed-pathology cases.
People With LATE Dementia Often Appear Cognitively Normal — Even as Brain Damage Accumulates
An autopsy-confirmed study of 686 older adults found that those with LATE — a TDP-43 brain disease distinct from Alzheimer's — were far more likely to appear cognitively intact at their initial clinical visit than those with Alzheimer's or combined disease. Over 40% of pure LATE patients were classified as cognitively normal at baseline, reported fewer memory complaints, and scored significantly better on neuropsychological testing. Symptoms emerged nearly six years later than in Alzheimer's patients. However, when LATE and Alzheimer's co-occurred, cognitive decline was dramatically accelerated — outperforming either disease alone across memory, language, processing speed, and executive function.
Source: Butler Pagnotti RM, et al. Neurology. 2023;100:e2027-e2035.
A Hidden Dementia Mimic Affects One in Three People Over 85 — And It's Not Alzheimer's
A consensus panel of leading neurologists has established the first clinical diagnostic criteria for LATE — limbic-predominant age-related TDP-43 encephalopathy — a progressive memory disorder affecting roughly a third of individuals over 85. LATE closely mimics Alzheimer's disease with hippocampal atrophy and episodic memory loss, yet it follows a slower, more isolated course and does not respond to anti-amyloid therapies. When LATE co-occurs with Alzheimer's, cognitive decline accelerates significantly. The criteria distinguish "probable" LATE (amyloid-negative) from "possible" LATE (amyloid-positive but with disproportionate hippocampal damage), offering clinicians a framework for more accurate diagnosis and treatment decisions.
Source: Wolk DA, Nelson PT, et al. Alzheimer's & Dementia. 2025;21:e14202.
Spinal Fluid Tau Markers Signal Alzheimer's Brain Changes Up to 13 Years Before Symptoms
A Johns Hopkins study of 120 cognitively unimpaired adults found that rising levels of phosphorylated tau (p-tau181) and total tau in cerebrospinal fluid were strongly linked to future tau accumulation in the brain's memory regions — specifically the entorhinal cortex and hippocampus, the earliest areas affected in Alzheimer's disease. Tracked over an average of 12.8 years, participants with steeper CSF tau trajectories showed significantly greater tau PET burden in Braak stage I and II regions. These findings suggest that spinal fluid biomarkers may serve as an early warning system for tau pathology long before any cognitive symptoms appear, offering a critical window for intervention.
Sensory Gamma Stimulation: A New Frontier in AD Treatment
This essay explores the innovative use of noninvasive sensory stimulation—specifically 40-Hz (Gamma) light and sound—to combat Alzheimer’s Disease (AD). Pioneered by researchers at MIT, this approach, known as GENUS (Gamma Entrainment Using Sensory Stimuli), has demonstrated the ability to reduce amyloid and tau levels and prevent neuronal loss in animal models. The stimulation works by "entraining" brain rhythms, which in turn recruits microglia (the brain's immune cells) to become more active in clearing pathological proteins and widening the diameter of brain blood vessels to improve waste clearance. Preliminary human trials show that the treatment is safe, well-tolerated, and can strengthen functional connectivity between brain regions. By leveraging the brain's natural electrical rhythms to drive biological repair, 40-Hz stimulation represents a cutting-edge intervention within the Neuro-Inflammation and Physical Foundations pillars.
Gamma Music-Based Interventions and Dementia Pathophysiology
This review explores the therapeutic potential of combining music-based interventions (MBIs) with Gamma-frequency stimulation (e.g., 40 Hz) to treat Alzheimer’s disease. Emerging research suggests that Gamma-frequency sensory stimulation can remediate multiple pathophysiologies, including the reduction of amyloid plaques and tau tangles, while restoring neural oscillations. By integrating these rhythmic stimuli into music, researchers hypothesize a synergistic effect that engages auditory-reward networks and promotes neuroprotection. This dual approach aims to bridge molecular-level repair with systems-level cognitive improvement. By modulating neural firing patterns and enhancing waste clearance, Gamma MBIs offer a non-invasive strategy to support the Neuro-Inflammation and Physical Foundations pillars of brain health.
AS01-Adjuvanted Vaccination and Lower Risk of Dementia
This large-scale propensity-score matched cohort study investigated the association between AS01-adjuvanted vaccines and dementia risk. By analyzing over 430,000 individuals, researchers found that both the recombinant shingles vaccine (Shingrix) and the recently introduced RSV vaccine—both of which utilize the AS01 adjuvant system—were associated with a significantly lower 18-month risk of dementia compared to non-adjuvanted vaccines. Because the protective effect was consistent across different pathogens (Varicella-Zoster and RSV), the findings suggest that the AS01 adjuvant itself may exert direct neuroprotective effects. The mechanism likely involves the systemic modulation of the innate immune system, potentially resolving chronic low-grade inflammation. By leveraging specific vaccine technologies to dampen maladaptive immune responses, this intervention targets Neuro-Inflammation to preserve long-term cognitive health.